Effects of Dynorphin 1-13 on Heroin Addiction - 1
Launched by UNIVERSITY OF MINNESOTA · Sep 20, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
Randomized double blinded study of the effects of a single IV dose of dynorphin A 1-13 on heroin withdrawal in human opiate addicts
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • opiate addict between the ages of 18-55
- Exclusion Criteria:
- • Regular abuse of other drugs, unstable medical conditions
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Paul Pentel, M.D.
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials